{(S)-1-[1-Hydroxy-2-(pyridine-2-sulfonylamino)-ethyl]-pentyl}-carbamic acid tert-butyl ester | 511268-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: {(S)-1-[1-Hydroxy-2-(pyridine-2-sulfonylamino)-ethyl]-pentyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl (1S)-1-{(1SR)-1-hydroxy-2-[(2-pyridinylsulfonyl)amino]ethyl}pentylcarbamate；tert-butyl N-[(3S)-2-hydroxy-1-(pyridin-2-ylsulfonylamino)heptan-3-yl]carbamate
• CAS: 511268-26-1
• 化学式: C₁₇H₂₉N₃O₅S
• 分子量: 387.5
• InChiKey: PWSSWIBCRLMEPW-LSLKUGRBSA-N

物化性质

• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  {(S)-1-[1-Hydroxy-2-(pyridine-2-sulfonylamino)-ethyl]-pentyl}-carbamic acid tert-butyl ester 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 {(S)-1-[1-Hydroxy-2-(pyridine-2-sulfonylamino)-ethyl]-pentyl}-carbamic acid (S)-2,2-dimethyl-1-[3-(4-trifluoromethyl-phenyl)-pyrazol-1-ylmethyl]-propyl ester
  参考文献：
  名称：

  Acyclic, orally bioavailable ketone-based cathepsin K inhibitors

  摘要：

  Starting from a potent ketone-based inhibitor with poor drug properties, incorporation of p(2)-p(3) elements from a ketoamide-based inhibitor led to the identification of a hybrid series of ketone-based cathepsin K inhibitors with better oral bioavailability than the starting ketone. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.102
• 作为产物：
  描述：

  [(S)-1-(Cyano-hydroxy-methyl)-pentyl]-carbamic acid tert-butyl ester 在 PtO₂/C 氢气 、 碳酸氢钠 、 溶剂黄146 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 {(S)-1-[1-Hydroxy-2-(pyridine-2-sulfonylamino)-ethyl]-pentyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Acyclic, orally bioavailable ketone-based cathepsin K inhibitors

  摘要：

  Starting from a potent ketone-based inhibitor with poor drug properties, incorporation of p(2)-p(3) elements from a ketoamide-based inhibitor led to the identification of a hybrid series of ketone-based cathepsin K inhibitors with better oral bioavailability than the starting ketone. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.102

文献信息

• Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
  申请人：Deaton Norman David

  公开号：US20050043368A1

  公开（公告）日：2005-02-24

  The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors. The described invention also includes methods of making such ketone derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis.

  本发明涉及酮衍生物（I）和（II），其作为猫hepsin K抑制剂具有用途。所述发明还包括制备此类酮衍生物的方法，以及使用它们治疗疾病的方法，包括骨质疏松症。
• Acyclic, orally bioavailable ketone-based cathepsin K inhibitors
  作者：David G. Barrett、John G. Catalano、David N. Deaton、Stacey T. Long、Robert B. McFadyen、Aaron B. Miller、Larry R. Miller、Vicente Samano、Francis X. Tavares、Kevin J. Wells-Knecht、Lois L. Wright、Hui-Qiang Q. Zhou

  DOI：10.1016/j.bmcl.2006.10.102

  日期：2007.1

  Starting from a potent ketone-based inhibitor with poor drug properties, incorporation of p(2)-p(3) elements from a ketoamide-based inhibitor led to the identification of a hybrid series of ketone-based cathepsin K inhibitors with better oral bioavailability than the starting ketone. (c) 2006 Elsevier Ltd. All rights reserved.